<p>Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 datasets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations.</p>

Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 datasets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations.

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.

Share Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer

Sign up to save your podcasts

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer

More shows like Lung Cancer Update

Gastrointestinal Cancer Update

Prostate Cancer Update

Breast Cancer Update

Gynecologic Oncology Update

Hematologic Oncology Update

Dermatologic Oncology Update

Lung Cancer CancerCare Connect Education Workshops

NEJM This Week

Journal of Clinical Oncology (JCO) Podcast

Research To Practice | Oncology Videos

ASCO Daily News

The Long Run with Luke Timmerman

ASCO Guidelines

Lung Cancer Considered

Oncology Today with Dr Neil Love

Business Of Biotech

Two Onc Docs